Giovanni Concistre

Dr. Giovanni Concistre

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
GCGiovanni Casali
Giovanni Casali
ESEugenio Santaniello
Eugenio Santaniello
AMAndrea Montalto
Andrea Montalto
BFBrenno Fiorani
Brenno Fiorani
FMFrancesco Musumeci
Francesco Musumeci

1 January 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
FCFrancesca Chiaramonti
Francesca Chiaramonti
Giacomo BianchiGiacomo Bianchi
Giacomo Bianchi
ACAlfredo Giuseppe Cerillo
Alfredo Giuseppe Cerillo
MMMichele Murzi
Michele Murzi
MSMarco Solinas
Marco Solinas

1 July 2020 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MSMarco Solinas
Marco Solinas
GBGiacomo Bianchi
Giacomo Bianchi
FCFrancesca Chiaramonti
Francesca Chiaramonti
RMRafik Margaryan
Rafik Margaryan
EKEnkel Kallushi
Enkel Kallushi
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
Background: A minimally invasive approach (MIA) reduces mortality and morbidity in patients referred for aortic valve replacement (AVR). Sutureless technology facilitates a MIA. We describe our experience with the sutureless Perceval (LivaNova, Italy) aortic bioprosthesis through a right anterior mini-thoracotomy (RAMT) approach. Methods: Between March 2011 and October 2019, 1,049 patients underwent AVR with Perceval bioprosthesis. Five hundred and three patients (48%) were operated through a RAMT approach in the second intercostal space. Considering only isolated AVR (881), 98% of patients were operated with MIA, and Perceval in RAMT approach was performed in 57% of these patients. Eight patients (1.6%) had previously undergone cardiac surgery. The prosthesis sizes implanted were: S (n=91), M (n=154), L (n=218) and XL (n=40). Concomitant procedures were mitral valve surgery (n=6), tricuspid valve repair (n=1), mitral valve repair and tricuspid valve repair (n=1) and miectomy (n=2). Mean age was 78±4 years (range, 65–89 years), 317 patients were female (63%) and EuroSCORE II was 5.9%±8.4%. Results: The 30-day mortality was 0.8% (4/503). Cardiopulmonary bypass (CPB) and aortic cross-clamp times were 81.6±30.8 and 50.3±24.5 minutes respectively for stand-alone procedures. In two patients, early moderate paravalvular leakage appeared as a result of incomplete expansion of the sutureless valve due to oversizing of the bioprosthesis, requiring reoperations at two and nine postoperative days with sutured aortic bioprosthesis implantation. Permanent pacemaker implantation within the first thirty days was necessary in 26 (5.2%) patients. At the mean follow-up of 4.6 years (range, 1 month to 8.6 years), survival was 96%, freedom from reoperation was 99.2%, and mean transvalvular pressure gradient was 11.9±4.3 mmHg. Conclusions: AVR with the Perceval bioprosthesis in a RAMT approach is a safe and feasible procedure associated with low mortality and excellent hemodynamic performance. Sutureless technology facilitates a RAMT approach.

22 May 2012 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
GSGiuseppe Santarpino
Giuseppe Santarpino
SPSteffen Pfeiffer
Steffen Pfeiffer
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
TFTheodor Fischlein
Theodor Fischlein
The Perceval S bioprosthesis (21 and 23 mm) was approved for clinical use in December 2010 and it is now routinely used. This bioprosthesis is suggested for the treatment of patients undergoing minimally-invasive surgery for reasons of safety and reduction in implantation time. Here we describe the use of the Perceval bioprosthesis in patients undergoing minimally invasive cardiac surgery.

1 June 2023 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
MBMax Baghai
Max Baghai
GSGiuseppe Santarpino
Giuseppe Santarpino
Alistair RoyseAlistair Royse
Alistair Royse
MSMaximilian Scherner
Maximilian Scherner
MSMarco Solinas
Marco Solinas
OBJECTIVES: Perceval sutureless valve has been in clinical use for >15 years. The aim of this study is to report the real-word clinical and haemodynamic performance from the SURE-aortic valve replacement international prospective registry in patients who underwent aortic valve replacement with Perceval valve. METHODS: From 2011 to 2021, patients from 55 institutions received a Perceval valve. Postoperative, follow-up, and echocardiographic outcomes were analysed. RESULTS: A total of 1652 patients were included; mean age was 75.3 ± 7.0 years (53.9% female); mean EuroSCORE II was 4.1 ± 6.3. Minimally invasive approach was performed in 45.3% of patients; concomitant procedures were done in 35.9% of cases. Within 30 days, 0.3 and 0.7% valve-related reinterventions were reported. Transient ischaemic attack, disabling and non-disabling strokes were limited (0.4%, 0.4% and 0.7%, respectively). Pacemaker implant was required in 5.7% of patients. Intra-prosthetic regurgitation ≥2 was present in 0.2% of cases, while paravalvular leak ≥2 in only 0.1%. At a maximum follow-up of 8 years, 1.9% of cardiovascular deaths and 0.8% of valve-related reintervention occurred. Among the 10 cases of structural valve deterioration (mean 5.6 ± 1.4 years after implant; range: 2.6–7.3 years), 9 were treated with a transcatheter vale-in-valve implantation and 1 with explant. Mean pressure gradient decreased from 45.8 ± 16.5 mmHg preoperatively to 13.3 ± 5.2 mmHg at discharge and remained stable during follow-up. CONCLUSIONS: This experience represents the largest prospective real-world cohort of patients treated with Perceval showing that Perceval is a safe and effective alternative to conventional surgical aortic valve replacement, providing favourable clinical and haemodynamic results also at mid-term follow-up.

2 March 2012 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
Giovanni ConcistreGiovanni Concistre
Giovanni Concistre
AMAntonio Miceli
Antonio Miceli
FCFrancesca Chiaramonti
Francesca Chiaramonti
MGMattia Glauber
Mattia Glauber
Sutureless aortic bioprosthesis implantation is an alternative technique in high-risk patients undergoing aortic valve replacement with a possible reduction in the extracorporeal circuit time and reliable haemodynamic features. A 3F Enable (ATS Medical—Medtronic, Inc., Minneapolis, MN, USA) has shown very good results. We report the first upward displacement of 3F Enable three months post implantation.